Home > Insider Trading > Filing (0001209191-17-048604)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
827871	Eagle Pharmaceuticals Inc.	EGRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1495110	L Douglas Braunstein	C/O Hudson Executive Capital Lp 1185 Avenue Of The Americas, 32Nd Floor New York NY 10036		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-08-09	3,610	$48.06	954,210	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2017-08-09	15,206	$49.21	969,416	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2017-08-09	1,584	$50.09	971,000	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $47.67 to $48.665, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (3), and (4) to this Form 4.
These securities are held for the account of certain private investment funds (the "HEC Funds") for which Hudson Executive Capital LP, a Delaware limited partnership ("HEC"), acts as investment adviser. The Reporting Person controls the general partner of HEC and indirectly controls the general partner of the HEC Funds. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in them.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.73 to $49.58, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $49.815 to $50.39, inclusive.